EUVIMEDEUVIMED entdecken
Crossref

Oleuropein mitigates non‐alcoholic fatty liver disease (NAFLD) and modulates liver metabolites in high‐fat diet‐induced obese mice via activating PPARα

Wei Zhou, Zheng Du

Journal of the Science of Food and Agriculture · 2024

DOI: 10.1002/jsfa.13691 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Science of Food and Agriculture, 2024. Verfasst von Wei Zhou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Prevention and Treatment of Cardiovascular Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Iridoid Glucosides, PPAR alpha, Mice, Inbred C57BL. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND This study aimed to elucidate the mechanism of oleuropein (OLE) ameliorates non‐alcoholic fatty liver disease (NAFLD) and its underlying mechanisms. RESULTS Male C57BL/6J mice were fed either a low‐fat diet (LFD), a high‐fat diet (HFD), or a HFD supplemented with 0.03% ( w/w ) OLE for 16 weeks. OLE supplementation decreased body weight and liver weight, improved serum lipid profiles, and ameliorated HFD‐induced hepatic dysfunction. Liver metabolomics analysis revealed that OLE increased the levels of nicotinamide, tauroursodeoxycholic acid, taurine, and docosahexaenoic acid, which were beneficial for lipid homeostasis and inflammation regulation. OLE exerted its protective effects by activating peroxisome proliferator‐activated receptor alpha (PPARα), a key transcription factor that regulates fibroblast growth factor 21 (FGF21) expression and modulates lipid oxidation, lipogenesis and inflammation pathways. Importantly, OLE supplementation did not significantly affect body weight or liver weight in PPARα knockout (PPARα KO) mice, indicating that PPARα is essential for OLE‐mediated NAFLD prevention. CONCLUSION Our results suggest that OLE alleviates NAFLD in mice by activating PPARα and modulating liver metabolites. © 2024 Society of Chemical Industry.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseIridoid GlucosidesPPAR alphaMice, Inbred C57BLDiet, High-FatLiverObesityAnimalsMaleMiceHumansMice, ObeseFibroblast Growth FactorsIridoidsLipid MetabolismMice, Knockout

Stichwörter der Autor:innen

FGF21NAFLDPPARαlipid metabolismoleuropein

Substanzen

Iridoid GlucosidesPPAR alphaoleuropeinFibroblast Growth Factorsfibroblast growth factor 21IridoidsPpara protein, mouse

Autor:innen und Institutionen

  • Center for Prevention and Treatment of Cardiovascular Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • The First People's Hospital of Lianyungang Public Health Department, Lianyungang, China.

Zitieren

APA

Zhou, W., & Du, Z. (2024). Oleuropein mitigates non‐alcoholic fatty liver disease (NAFLD) and modulates liver metabolites in high‐fat diet‐induced obese mice via activating PPARα. Journal of the Science of Food and Agriculture. https://doi.org/10.1002/jsfa.13691

Vancouver

Zhou W, Du Z. Oleuropein mitigates non‐alcoholic fatty liver disease (NAFLD) and modulates liver metabolites in high‐fat diet‐induced obese mice via activating PPARα. Journal of the Science of Food and Agriculture. 2024. doi:10.1002/jsfa.13691

BibTeX
@article{Zhou2024,
  author = {Zhou, Wei and Du, Zheng},
  title = {Oleuropein mitigates non‐alcoholic fatty liver disease (NAFLD) and modulates liver metabolites in high‐fat diet‐induced obese mice via activating PPARα},
  journal = {Journal of the Science of Food and Agriculture},
  year = {2024},
  doi = {10.1002/jsfa.13691}
}
Kostenlos starten →